Genetic studies on investigative embryos
During the course of an IVF treatment some fertilised eggs might not develop in a way that makes them suitable candidates for transfer. These clinically unsuitable embryos that are usually discarded can alternatively be handed to our research laboratories where we can carry out certain investigations that might give valuable information for the IVF patient. These studies comprise genetic testing like determination of possible chromosomal abnormalities, genetic mutations, DNA damage and/or abnormal gene expression. In order for us to be able to perform these studies, interested patients have to give consent. The consent form called Investigating embryos not suitable for transfer can be obtained from any of our clinical staff.
This option is unique to Sydney IVF and is offered free of charge for the patients.
Embryo and oocyte cryostorage
Sydney IVF has always been at the forefront of bringing new reproductive technologies to patients. Our multinational, multi-centre research and clinical team work together to accelerate the clinical implementation of new ART techniques. One such technology is the technique called vitrification (for cryopreservation of embryos). Our innovative blastocyst vitrification protocol has been in use at Sydney IVF since 2006. Vitrification involves the "snap-freezing" of the embryo at the blastocyst stage (day 5-7 of development) and is much less damaging than the traditional slow freeze process. The big advantages of vitrification over slow-freezing are its simplicity and a 98% embryo survival rate. At Sydney IVF, we have found that the pregnancy rate for women under 38 who had blastocyst transfer was higher with vitrified embryos (47%) compared to slow-frozen embryos (35%, for January to November in 2006).
Our oocyte and cleavage stage vitrification program is currently evaluated in a multinational multi-centre trial. The cryopreservation of human oocytes offers advantages for patients as it can be used for cycles complicated by ovarian hyperstimulation syndrome, failure to obtain sperm and to avoid synchronization issues in oocyte-donation cycles. This technology may also be used for fertility preservation with patients faced with a diagnosis of cancer and subsequent chemotherapy. Reliable and safe oocyte preservation is also essential for research on somatic cell nuclear transfer to be used for the development of new therapeutics for diseases such as Parkinson's, and diabetes. Once again, we are leading in the implementation of safe and reliable modern ART techniques and maintaining Sydney IVF's world class clinical service, through cutting edge research and development.
Miscarriage analysis
To elucidate mechanisms responsible for failed embryo development and implantation the research department is running genetic studies on DNA provided by patients who are unfortunate in having recurring miscarriages. The studies aim to identify genes that are commonly associated with recurring miscarriage and ultimately develop potential preventative treatments. We are currently examining genes associated with DNA processing pathways as well as genes that are influenced by nutrition. It is not expected that a single gene will be responsible for all miscarriage causes but such studies may be useful in reducing the impact of common genetic variations in the miscarriage process.